XML 17 R3.htm IDEA: XBRL DOCUMENT v3.21.2
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
 3 Months Ended 9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
Revenues:        
Total revenues $ 291,698 $ 236,178 $ 935,643 $ 1,830,639
Operating expenses:        
Research and development 47,088,669 26,455,112 156,941,505 67,942,875
General and administrative 13,156,183 10,110,506 39,703,718 28,630,370
Total operating expenses 60,244,852 36,565,618 196,645,223 96,573,245
Loss from operations (59,953,154) (36,329,440) (195,709,580) (94,742,606)
Other income (expense):        
Interest income 766,271 896,710 2,463,618 2,380,678
Interest expense (476,374) (1,984,046) (1,456,134) (7,634,442)
Change in fair value of derivative liability 0 35,306,000 0 (75,670,977)
Gain (loss) on investment in affiliated entities (21,999) 26,951,898 (573,656) 36,250,341
Net unrealized gain (loss) on available-for-sale equity securities (455,299) 1,315,980 (1,166,764) 624,522
Other income (expense), net (28,486) (136,644) 165,773 (714,246)
Gain on deconsolidation of Geneos 0 0 0 4,121,075
Net income (loss) before share in net loss of Geneos (60,169,041) 20,931,010 (196,276,743) (140,475,103)
Share in net loss of Geneos 0 (1,759,674) (434,387) (2,661,431)
Net income (loss) (60,169,041) 19,171,336 (196,711,130) (143,136,534)
Net loss attributable to non-controlling interest 0 0 0 1,063,757
Net income (loss) attributable to Inovio Pharmaceuticals, Inc. $ (60,169,041) $ 19,171,336 $ (196,711,130) $ (142,072,777)
Net income (loss) per share attributable to Inovio Pharmaceuticals, Inc. stockholders        
Basic (in dollars per share) $ (0.29) $ 0.12 $ (0.95) $ (0.96)
Diluted (in dollars per share) $ (0.29) $ 0.11 $ (0.95) $ (0.96)
Weighted average number of common shares outstanding        
Basic (in shares) 210,304,836 165,355,540 207,455,684 148,656,454
Diluted (in shares) 210,304,836 174,376,402 207,455,684 148,656,454
Convertible bonds        
Other income (expense):        
Gain on extinguishment of convertible senior notes $ 0 $ (8,177,043) $ 0 $ (8,177,043)
Convertible senior notes        
Other income (expense):        
Gain on extinguishment of convertible senior notes 0 3,087,595 0 3,087,595
Revenue under collaborative research and development arrangements        
Revenues:        
Total revenues 81,447 21,490 203,985 167,092
Revenue under collaborative research and development arrangements with affiliated entities        
Revenues:        
Total revenues 95,136 103,684 219,872 1,370,956
Other revenue        
Revenues:        
Total revenues $ 115,115 $ 111,004 $ 511,786 $ 292,591